

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised that the shortages for the following products have been resolved by their respective manufacturers.

DIN/NPN	Product description	Manufacturer
02399105	Apo-Candesartan 32 mg Tablet	Apotex Inc
02435845	Candesartan 32 mg Tablet	Sanis Health Inc.
02379295	Candesartan Cilexetil 32 mg Tablet	Accord Healthcare Inc
02386534	Jamp-Candesartan 32 mg Tablet	Jamp Pharma Corporation
02391228	pms-Candesartan 32 mg Tablet	Pharmascience Inc.
02417340	Sandoz Candesartan 32 mg Tablet	Sandoz Canada Inc.
02366339	Teva-Candesartan 32 mg Tablet	Teva Canada Limited

Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 13, 2021**. The following grouping was removed from the Critical Supply Product List **December 14, 2020**.

CANDESARTAN CILEXETIL

32 MG TABLET

00002399105	APO-CANDESARTAN	APX	\$ 0.2281
00002445816	AURO-CANDESARTAN	AUR	\$ 0.2281
00002435845	CANDESARTAN	SNS	\$ 0.2281
00002379295	CANDESARTAN CILEXETIL	AHI	\$ 0.2281
00002386534	JAMP-CANDESARTAN	JPC	\$ 0.2281
00002391228	PMS-CANDESARTAN	PMS	\$ 0.2281
00002380714	RAN-CANDESARTAN	RAN	\$ 0.2281
00002417340	SANDOZ CANDESARTAN	SDZ	\$ 0.2281
00002366339	TEVA-CANDESARTAN	TEV	\$ 0.2281
00002311658	ATACAND	AZC	\$ 1.2847

... continued from previous page

Alberta Blue Cross has been advised by Actavis Pharma Company and Apotex Inc. that the shortages for Act Raloxifene 60 mg Tablet (DIN 02358840) and Apo-Raloxifene 60 mg Tablet (DIN 02279215) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 6, 2021**. The following grouping was removed from the Critical Supply Product List **December 7, 2020**.

RALOXIFENE HCL

60 MG TABLET

00002358840	ACT RALOXIFENE	APH	\$ 0.4583
00002279215	APO-RALOXIFENE	APX	\$ 0.4583
00002239028	EVISTA	LIL	\$ 1.9593

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Budesonide 0.5 mg/ml Inhalation Suspension (DIN 02465957) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 11, 2021**. The following grouping was removed from the Critical Supply Product List **December 11, 2020**.

BUDESONIDE

0.5 MG / ML INHALATION SUSPENSION

00002465957	TEVA-BUDESONIDE	TEV	\$ 0.6839
00001978926	PULMICORT NEBUAMP	AZC	\$ 0.9473

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

